Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 19 Lung Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 8 Prostatic Neoplasms 6 Prostatic Neoplasms, Castration-Resistant 4 Stomach Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Endometrial Neoplasms 3 Carcinoma, Transitional Cell 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Melanoma 2 Lymphoid Interstitial Pneumonia 2 Head and Neck Neoplasms 2 Esophageal Neoplasms 2 Carcinoma 2 Vaccinia 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Tongue Neoplasms 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Non-muscle Invasive Bladder Cancer With Carcinoma in Situ 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1

Interventions

aflutinib 1 HM781-36B 1 Docetaxel 1 Anterior Temporal Lobectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Docetaxel × 30 days × Clear all

NCT05378763 2026-05-22

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡